MedTrace Logo

Short-term Disulfiram Administration to Reverse Latent HIV Infection: a Dose Escalation Study

NCT01944371 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2020-05-05

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the safety, pharmacology and bioactivity of disulfiram in antiretroviral treated HIV-infected adults. The investigators primary hypothesis is that 3 days of disulfiram will result in an increase in HIV transcription in CD4+ T-cells in patients on suppressive antiretroviral therapy (ART).

Conditions

  • HIV
  • Human Immunodeficiency Virus

Interventions

DRUG

Disulfiram

This study will provide open label disulfiram. Subjects will take 1 dose of disulfiram per day for 3 days.

Sponsors & Collaborators

Principal Investigators

  • Steven Deeks, MD · University of Californa, San Francisco

  • Julian Elliott, MD · Monash University

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2014-05-31
Completion
2014-05-31

Countries

  • United States
  • Australia

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01944371 on ClinicalTrials.gov